Theratechnologies Short ratio
What is the Short ratio of Theratechnologies?
The Short ratio of Theratechnologies, Inc. is 4.16
What is the definition of Short ratio?
Short ratio is the number of shares sold short divided by the average daily volume.
= short interest / average daily volume
Short ratio is calculated by dividing the number of shares sold short by the average daily trading volume, generally over the last 30 trading days. The ratio represents the number of days it takes short sellers on average to repurchase all the borrowed shares. The ratio is used by both fundamental and technical traders to identify trends.
The percentage represents the number of days it takes short sellers on average to repurchase all the borrowed shares. Short selling is the practice of selling securities or other financial instruments that are not currently owned, and subsequently repurchasing them. In the event of an interim price decline, the short seller profits, since the cost of (re)purchase is less than the proceeds received upon the initial (short) sale. Conversely, the short position closes out at a loss if the price of a shorted instrument rises prior to repurchase. A high short ratio can be an indicator that there will be some buying pressure on the security that would increase its price.
Short ratio of companies in the Health Care sector on TSX compared to Theratechnologies
What does Theratechnologies do?
Theratechnologies Inc., a biopharmaceutical company, focuses on the development and commercialization of various therapies to address the unmet medical needs in the United States, Canada, and Europe. The company offers EGRIFTA and EGRIFTA SV, for the reduction of excess abdominal fat in human immunodeficiency virus (HIV)-infected patients with lipodystrophy; and Trogarzo, an injection refers to ibalizumab for the treatment of multidrug resistant HIV-1 infected patients. Its pipeline products include F8 Formulation for the treatment of lipodystrophy in people living with HIV; TH-1902 for the treatment of triple negative breast cancer; and TH-1904 for the treatment of ovarian cancer. The company was incorporated in 1993 and is headquartered in Montreal, Canada.
Companies with short ratio similar to Theratechnologies
- Mackinac has Short ratio of 4.15
- Stella-Jones has Short ratio of 4.15
- QCR has Short ratio of 4.15
- VYNE Therapeutics has Short ratio of 4.15
- Eastern Bankshares has Short ratio of 4.15
- Pacific Biosciences of California Inc has Short ratio of 4.15
- Theratechnologies has Short ratio of 4.16
- Galapagos NV has Short ratio of 4.17
- Alcon has Short ratio of 4.17
- Heartland USA has Short ratio of 4.17
- Lovesac has Short ratio of 4.17
- CNOOC has Short ratio of 4.17
- Helios Technologies has Short ratio of 4.17